GlassScriptPhysician profile
William L Ebbeling
NPI 1205808284
$1,177.83
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $166.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $300.40 | 2019-2020 | |
| Octapharma USA, INC. | $239.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $235.86 | 2019-2020 | |
| Shire North American Group INC | $75.64 | 2019 | |
| Optinose US, INC. | $75.00 | 2019-2020 | |
| Kaleo, INC. | $59.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.86 | 2020 | |
| Genzyme Corporation | $21.94 | 2019 | |
| Bio Products Laboratory USA, INC. | $21.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.62 | 2019 | |
| Alk-Abello, INC | $15.17 | 2019 | |
| Csl Behring | $12.75 | 2019 | |
| Pfizer INC. | $12.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ebbeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.